The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
The Limitless Future of RNA Therapeutics
Open accessAbstract
Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00402 · Cited by 5,287
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Biodegradable polymeric nanoparticles based drug delivery systems
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.09.001 · Cited by 3,724
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Gilbert, W. (1986) · Nature · doi:10.1038/319618a0 · Cited by 2,721
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.12.5429-5433.1987 · Cited by 2,421
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
CRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform
Zhang, L., Chan, J. M., Gu, F. X., Rhee, J.-W., Wang, A. Z., Radovic-Moreno, A. F., Alexis, F., Langer, R., & Farokhzad, O. C. (2008) · ACS Nano · doi:10.1021/nn800275r · Cited by 1,038
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Antisense oligonucleotides: basic concepts and mechanisms.
Dias, N., & Stein, C. A. (2002) · PubMed · Cited by 948
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Kam, N. W. S., Liu, Z., & Dai, H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053962k · Cited by 784
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., Dawkins, H., Lamont, L., Roy, A. J., Chamova, T., et al. (2015) · Human Mutation · doi:10.1002/humu.22758 · Cited by 729
The Potential for microRNA Therapeutics and Clinical Research
Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 726
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review
Hadinoto, K., Sundaresan, A., & Cheow, W. S. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.07.002 · Cited by 702
Preparation, Characterization and Applications of Liposomes: State of the Art
Laouini, A., Jaafar-Maalej, C., Limayem-Blouza, I., Sfar, S., Charcosset, C., & Fessi, H. (2012) · Journal of Colloid Science and Biotechnology · doi:10.1166/jcsb.2012.1020 · Cited by 692
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 607
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes
Ezkurdia, I., Juan, D., Rodriguez, J. M., Frankish, A., Diekhans, M., Harrow, J., Vazquez, J., Valencia, A., & Tress, M. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu309 · Cited by 549
Stimuli-responsive nanogel composites and their application in nanomedicine
Molina, M., Asadian-Birjand, M., Balach, J., Bergueiro, J., Miceli, E., & Calderón, M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00199d · Cited by 529
Molecular Mechanisms and Biological Functions of siRNA
Department of Biology, D. B., Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzlo, E., Cancer Research Center, C. I. O. I., Karimloo, R., Department of Medicine, Z. M. S., Rezaiean, O., Moradzadeh, A., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 505
Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501
Eteplirsen in the treatment of Duchenne muscular dystrophy
Lim, K. R., Maruyama, R., & Yokota, T. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97635 · Cited by 495
The genetic sequence, origin, and diagnosis of SARS-CoV-2
Wang, H., Li, X., Li, T., Zhang, S., Wang, L., Wu, X., & Liu, J. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03899-4 · Cited by 491
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., Zhou, J., Bouton, C. R., Rogers, P., Polra, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17409-9 · Cited by 462
Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454
Biomimetic proteolipid vesicles for targeting inflamed tissues
Molinaro, R., Corbo, C., Martinez, J. O., Taraballi, F., Evangelopoulos, M., Minardi, S., Yazdi, I. K., Zhao, P., De Rosa, E., Sherman, M. B., et al. (2016) · Nature Materials · doi:10.1038/nmat4644 · Cited by 451
Self-citationDevelopments in Viral Vector-Based Vaccines
Ura, T., Okuda, K., & Shimada, M. (2014) · Vaccines · doi:10.3390/vaccines2030624 · Cited by 436
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 427
Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
Zheng, D., Giljohann, D. A., Chen, D. L., Massich, M. D., Wang, X.-Q., Iordanov, H., Mirkin, C. A., & Paller, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118425109 · Cited by 409
Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Maintaining safety with SARS-CoV-2 vaccines
Castells, M. C., & Phillips, E. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2035343 · Cited by 395
Baker, B. F., Lot, S. S., Condon, T. P., Cheng-Flournoy, S., Lesnik, E. A., Sasmor, H. M., & Bennett, C. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11994 · Cited by 371
Aptamers in the Therapeutics and Diagnostics Pipelines
Kaur, H., Bruno, J. G., Kumar, A., & Sharma, T. K. (2018) · Theranostics · doi:10.7150/thno.25958 · Cited by 366
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Talimogene laherparepvec: First in class oncolytic virotherapy
Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412896 · Cited by 335
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009233 · Cited by 332
(1995) · PubMed · Cited by 330
CRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 328
Therapeutic application of peptides and proteins: parenteral forever?
Antosova, Z., Mackova, M., Kral, V., & Macek, T. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.07.009 · Cited by 324
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 310
Dean, N. M., McKay, R., Condon, T. P., & Bennett, C. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34023-1 · Cited by 291
Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E. (1992) · Science · doi:10.1126/science.1546298 · Cited by 282
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1
Mamcarz, E., Zhou, S., Lockey, T., Abdelsamed, H., Cross, S. J., Kang, G., Ma, Z., Condori, J., Dowdy, J., Triplett, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815408 · Cited by 263
Minshull, J., & Hunt, T. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.16.6433 · Cited by 243
Reid, G., Kao, S. C., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., & van Zandwijk, N. (2016) · Epigenomics · doi:10.2217/epi-2016-0035 · Cited by 242
Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 230
John, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.029 · Cited by 229
Ledwith, B. J., Manam, S., Troilo, P. J., Barnum, A. B., Pauley, C. J., Griffiths II, T. G., Harper, L. B., Beare, C. M., Bagdon, W. J., & Nichols, W. W. (2000) · Intervirology · doi:10.1159/000053993 · Cited by 218
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
Zimmermann, T. S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B. R., Hutabarat, R., Nochur, S., Vaishnaw, A., & Gollob, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.019 · Cited by 216
Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.
Santulli-Marotto, S., Nair, S. K., Rusconi, C. P., Sullenger, B. A., & Gilboa, E. (2003) · PubMed · Cited by 214
Zhang, X., Goel, V., & Robbie, G. J. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1553 · Cited by 213
Liang, X.-H., Shen, W., Sun, H., Migawa, M. T., Vickers, T. A., & Crooke, S. T. (2016) · Nature Biotechnology · doi:10.1038/nbt.3589 · Cited by 212
Volanesorsen: First Global Approval
Paik, J., & Duggan, S. (2019) · Drugs · doi:10.1007/s40265-019-01168-z · Cited by 208
Tratschin, J. D., West, M. H., Sandbank, T., & Carter, B. J. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.10.2072 · Cited by 202
Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202
Use of adeno-associated viral vector for delivery of small interfering RNA
Tomar, R. S., Matta, H., & Chaudhary, P. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206733 · Cited by 196
Shi, J., Xiao, Z., Votruba, A. R., Vilos, C., & Farokhzad, O. C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101554 · Cited by 196
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
Desai, P. R., Marepally, S., Patel, A. R., Voshavar, C., Chaudhuri, A., & Singh, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.021 · Cited by 188
Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation
Boada, C., Zinger, A., Tsao, C., Zhao, P., Martinez, J. O., Hartman, K., Naoi, T., Sukhovershin, R., Sushnitha, M., Molinaro, R., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.315185 · Cited by 186
Self-citationAssembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer
Dollins, C. M., Nair, S., Boczkowski, D., Lee, J., Layzer, J. M., Gilboa, E., & Sullenger, B. A. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.05.016 · Cited by 183
Carlsson, L., Clarke, J. C., Yen, C., Gregoire, F., Albery, T., Billger, M., Egnell, A.-C., Gan, L.-M., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 178
Targeting VEGF in eye neovascularization: What's new?
Amadio, M., Govoni, S., & Pascale, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.027 · Cited by 175
Yang, H.-W., Huang, C.-Y., Lin, C.-W., Liu, H.-L., Huang, C.-W., Liao, S.-S., Chen, P.-Y., Lu, Y.-J., Wei, K.-C., & Ma, C.-C. M. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.057 · Cited by 172
Antisense-based therapy for the treatment of spinal muscular atrophy
Rigo, F., Hua, Y., Krainer, A. R., & Bennett, C. F. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201207087 · Cited by 172
Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Zheng, P.-P., Kros, J. M., & Li, J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.02.012 · Cited by 171
Lincoff, A. M., Mehran, R., Povsic, T. J., Zelenkofske, S. L., Huang, Z., Armstrong, P. W., Steg, P. G., Bode, C., Cohen, M. G., Buller, C. E. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00515-2 · Cited by 167
Zhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.003 · Cited by 165
De Keersmaecker, B., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 165
Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
Neil, E. E., & Bisaccia, E. K. (2019) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-24.3.194 · Cited by 162
van der Ree, M. H., van der Meer, A. J., van Nuenen, A. C., de Bruijne, J., Ottosen, S., Janssen, H. L., Kootstra, N. A., & Reesink, H. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13432 · Cited by 159
Sebastian, M., Papachristofilou, A., Weiß, C., Früh, M., Cathomas, R. L., Hilbe, W., Wehler, T., Rippin, G., Koch, S. D., Scheel, B., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-748 · Cited by 155
Mullard, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00001-7 · Cited by 150
Sushnitha, M., Evangelopoulos, M., Tasciotti, E., & Taraballi, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00627 · Cited by 147
Self-citationSingh, H., Huls, H. M., Kebriaei, P., & Cooper, L. J. N. (2013) · Immunological Reviews · doi:10.1111/imr.12137 · Cited by 139
The 5′ and 3′ ends of alphavirus RNAs – Non-coding is not non-functional
Hyde, J., Chen, R., Trobaugh, D. W., Diamond, M., Weaver, S. C., Klimstra, W. B., & Wilusz, J. (2015) · Virus Research · doi:10.1016/j.virusres.2015.01.016 · Cited by 134
Möller, K., Müller, K., Engelke, H., Bräuchle, C., Wagner, E., & Bein, T. (2015) · Nanoscale · doi:10.1039/c5nr06246b · Cited by 133
Fully modified 2' MOE oligonucleotides redirect polyadenylation
Vickers, T. A. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.6.1293 · Cited by 132
Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA
Zhao, M., Li, M., Zhang, Z., Gong, T., & Sun, X. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1038856 · Cited by 132
Bauer, M., Strom, M., Hammond, D., & Shigdar, S. L. (2019) · Molecules · doi:10.3390/molecules24234377 · Cited by 131
Martinez, J. O., Molinaro, R., Hartman, K. A., Boada, C., Sukhovershin, R. A., Rosa, E. D., Kuri, D., Zhang, S., Evangelopoulos, M., Carter, A. M., et al. (2018) · Theranostics · doi:10.7150/thno.22078 · Cited by 122
Self-citationBerezhnoy, A., Stewart, C. A., McNamara, J. O., Thiel, W. H., Giangrande, P. H., Trinchieri, G., & Gilboa, E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.18 · Cited by 120
Giles, R. V., Spiller, D. G., & TIDD, D. M. (1995) · Antisense Research and Development · doi:10.1089/ard.1995.5.23 · Cited by 108
Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review
Paris, J. L., & Vallet‐Regí, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060526 · Cited by 107
Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging
Li, J., Zhao, M., Su, H., Wang, Y., Tan, C., Ji, L., & Mao, Z. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.011 · Cited by 104
Nusinersen for spinal muscular atrophy
Wurster, C. D., & Ludolph, A. C. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285618754459 · Cited by 104
Devulapally, R., Foygel, K., Sekar, T. V., Willmann, J. K., & Paulmurugan, R. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b08153 · Cited by 103
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 100
Schrand, B., Berezhnoy, A., Brenneman, R., Williams, A. J., Levay, A. K., Kong, L.-Y., Rao, G., Zhou, S., Heimberger, A. B., & Gilboa, E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0007 · Cited by 98
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
Mathew, V., & Wang, A. K. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s162913 · Cited by 95
Moyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
Recent innovations in mRNA vaccines
Ulmer, J. B., & Geall, A. J. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.008 · Cited by 91 · cited 2×
“The development of RNA drugs has largely focused on two approaches: (1) antisense RNA (RNAi), where short oligonucleotides recognize and hybridize to complementary sequences in endogenous RNA transcripts and alter their processing (Stephenson and Zamecnik, 1978; Shen and Corey, 2018); and (2) message RNA (mRNA), where…”
BackgroundHow COVID unlocked the power of RNA vaccines
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-00019-w · Cited by 90 · cited 1×
“…guanosine structure covalently joined to the first nucleotide of the mRNA through a reverse 5′ to 5′ triphosphate linkage (Kowalski et al., 2019; Dolgin, 2021); A, adenosine molecule; (A)n, poly-A tail; UTR, untranslated region. in clinical trials is BNT122 (phase II) from BioNTech, which is…”
BackgroundVogel, F. R., & Sarver, N. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.3.406 · Cited by 89
Different methods to determine the encapsulation efficiency of protein in PLGA nanoparticles
Amini, Y., Jamehdar, S. A., Sadri, K., Zare, S., Musavi, D., & Tafaghodi, M. (2017) · Bio-Medical Materials and Engineering · doi:10.3233/bme-171705 · Cited by 86
Hung, C., Xu, X., Li, L., Ma, Y., Qiu, J. F., Viley, A. M., Allen, C., Natarajan, P., Shivakumar, R., Peshwa, M. V., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.080 · Cited by 84
Corbo, C., Cromer, W. E., Molinaro, R., Furman, N. E. T., Hartman, K. A., Rosa, E. D., Boada, C., Wang, X., Zawieja, D. C., Agostini, M., et al. (2017) · Nanoscale · doi:10.1039/c7nr04734g · Cited by 82
Self-citationKunjin Virus Replicon Vaccine Vectors Induce Protective CD8+T-Cell Immunity
Anraku, I., Harvey, T. J., Linedale, R., Gardner, J., Harrich, D., Suhrbier, A., & Khromykh, A. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.3791-3799.2002 · Cited by 77
Double‐blind, placebo‐controlled study of HGF gene therapy in diabetic neuropathy
Kessler, J. A., Smith, A. G., Cha, B., Choi, S. H., Wymer, J., Shaibani, A. I., Ajroud‐Driss, S., Vinik, A. I., & VM202 DPN‐II Study Group (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.186 · Cited by 77
Onasemnogene abeparvovec for spinal muscular atrophy: The costlier drug ever
Mahajan, R. (2019) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_190_19 · Cited by 76
McCullough, K. C., Bassi, I., Milona, P., Suter, R., Thomann, L., Englezou, P. C., Démoulins, T., & Ruggli, N. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.24 · Cited by 72
Latest Development on RNA-Based Drugs and Vaccines
Lundstrom, K. H. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0151 · Cited by 72
mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency
Cao, J., An, D., Galduroz, M., Zhuo, J., Liang, S., Eybye, M., Frassetto, A., Kuroda, E., Funahashi, A., Santana, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.017 · Cited by 70
Self-Replicating RNA Viruses for RNA Therapeutics
Lundstrom, K. H. (2018) · Molecules · doi:10.3390/molecules23123310 · Cited by 70
Special Report: The birth of biotechnology
Russo, E. (2003) · Nature · doi:10.1038/nj6921-456a · Cited by 68
SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency
Connolly, B., Isaacs, C., Cheng, L., Asrani, K. H., & Subramanian, R. R. (2018) · Journal of Nucleic Acids · doi:10.1155/2018/8247935 · Cited by 67
Molinaro, R., Pastò, A., Corbo, C., Taraballi, F., Giordano, F., Martinez, J. O., Zhao, P., Wang, X., Zinger, A., Boada, C., et al. (2019) · Nanoscale · doi:10.1039/c9nr04253a · Cited by 61
Self-citationPlasmid DNA Manufacturing for Indirect and Direct Clinical Applications
Schmeer, M., Buchholz, T., & Schleef, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.159 · Cited by 59
Structural Elucidation of Post-Translational Modifications in Monoclonal Antibodies
Li, W., Kerwin, J. L., Schiel, J. E., Formolo, T., Davis, D., Mahan, A. D., & Benchaar, S. A. (2015) · ACS symposium series · doi:10.1021/bk-2015-1201.ch003 · Cited by 57
Lozano, T., Soldevilla, M. M., Casares, N., Villanueva, H., Bendandi, M., Lasarte, J. J., & Pastor, F. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.007 · Cited by 56
In vitro-Transcribed mRNA Therapeutics: Out of the Shadows and Into the Spotlight
Karikó, K. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.009 · Cited by 56
Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development
Harvey, T. J., Anraku, I., Linedale, R., Harrich, D., Mackenzie, J. M., Suhrbier, A., & Khromykh, A. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7796-7803.2003 · Cited by 54
Andreozzi, P., Diamanti, E., Py-Daniel, K. R., Cáceres‐Vélez, P. R., Martinelli, C., Πολιτάκος, Ν., Escobar, A., Muzi-Falconi, M., Azevedo, R. B., & Moya, S. E. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11132 · Cited by 53
Jagger, B. W., Dowd, K. A., Chen, R. E., Desai, P., Foreman, B., Burgomaster, K. E., Himansu, S., Kong, W.-P., Graham, B. S., Pierson, T. C., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz338 · Cited by 53
Schuessler‐Lenz, M., Enzmann, H., & Vamvakas, S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1639 · Cited by 50
CONDIT, R. C., Williamson, A., Sheets, R., Seligman, S. J., Monath, T. P. C., Excler, J., Gurwith, M., Bok, K., Robertson, J. S., Kim, D., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.060 · Cited by 46
CRISPR-Cas9: A New Addition to the Drug Metabolism and Disposition Tool Box
Karlgren, M., Simoff, I., Keiser, M., Oswald, S., & Artursson, P. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.082842 · Cited by 42
Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation
Schrand, B., Verma, B., Levay, A. K., Patel, S., Castro, I., Benaduce, A. P., Brenneman, R., Umland, O., Yagita∥, H., Gilboa, E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2105 · Cited by 39
Mechanisms of microRNA-mediated gene regulation in unicellular model alga Chlamydomonas reinhardtii
Lou, S., Sun, T., Li, H., & Hu, Z. (2018) · Biotechnology for Biofuels · doi:10.1186/s13068-018-1249-y · Cited by 38
Arance, A. M., Baurain, J., Vulsteke, C., Rutten, A., Soria, A., Carrasco, J., Neyns, B., Keersmaecker, B. D., Assche, T. V., & Lindmark, B. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2641 · Cited by 36
South, E., Cox, E. M., Meader, N., Woolacott, N. F., & Griffin, S. C. (2018) · PharmacoEconomics - Open · doi:10.1007/s41669-018-0102-3 · Cited by 32
Bioinspired Extracellular Vesicles: Lessons Learned From Nature for Biomedicine and Bioengineering
Zinger, A., Brozovich, A., Pastò, A., Sushnitha, M., Martinez, J. O., Evangelopoulos, M., Boada, C., Tasciotti, E., & Taraballi, F. (2020) · Nanomaterials · doi:10.3390/nano10112172 · Cited by 30
Self-citationDaley, J. (2019) · Nature · doi:10.1038/d41586-019-03716-9 · Cited by 28
(2020) · Nature Biotechnology · doi:10.1038/s41587-020-0494-3 · Cited by 27
DNA as Therapeutics; an Update
Saraswat, P., Soni, R., Bhandari, A., & Nagori, B. (2009) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.58169 · Cited by 22
mRNA Therapies: New Hope in the Fight against Melanoma
van Dülmen, M., & Rentmeister, A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00181 · Cited by 22
Cited by
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Hydrogel armed with Bmp2 mRNA-enriched exosomes enhances bone regeneration
Yang, Z., Li, X., Gan, X., Wei, M., Wang, C., Yang, G., Zhao, Y., Zhu, Z., & Wang, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01871-w · Cited by 109
Self-Amplifying RNA Approach for Protein Replacement Therapy
Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76
Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection
Tuma, J., Chen, Y.-J., Collins, M. G., Paul, A., Li, J., Han, H., Sharma, R., Murthy, N., & Lee, H. Y. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00371 · Cited by 65
RNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51
Metadata
- Authors
- Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P.
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-18
- Volume
- 9
- Pages
- 628137-628137
- ISSN
- 2296-4185 (ISSN-L)
- OpenAlex
- W3137008460
- Cited by
- 544
- References
- 163
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.